CalciMedica is trading 5.17% up now at $0.71 after closing at $0.68 on August 14, 2026; no new company-specific announcement directly explaining the after-hours move was identified.
- The latest major catalyst remains the August 11 earnings release: a $0.45-per-share loss alongside FDA alignment on Auxora’s Phase 2b acute-pancreatitis trial design.
- Coverage described investor focus on the company’s regulatory and pipeline progress despite the earnings miss.